tiprankstipranks
Trending News
More News >
Advertisement

XHE - ETF AI Analysis

Compare

Top Page

XHE

SPDR S&P Health Care Equipment ETF (XHE)

Rating:66Neutral
Price Target:
The SPDR S&P Health Care Equipment ETF (XHE) has a solid overall rating, reflecting a mix of strong performers and some weaker holdings. Globus Medical stands out as a key contributor, driven by its robust financial performance, strategic growth initiatives, and successful acquisitions. Inspire Medical Systems also adds positively with strong growth potential and financial momentum, though its high valuation poses a risk. On the other hand, AxoGen and Alphatec Holdings weigh down the rating due to profitability challenges and valuation concerns. The ETF's concentration in the healthcare equipment sector may expose it to risks tied to industry-specific challenges like regulatory changes or innovation cycles.
Positive Factors
Focused Sector Exposure
The ETF is heavily concentrated in the health care equipment sector, which can benefit from long-term demand for medical innovation.
Reasonable Expense Ratio
The fund charges a relatively low expense ratio, making it cost-effective compared to many actively managed funds.
Steady Recent Performance
The ETF has shown positive returns over the last three months, indicating some recovery in its holdings.
Negative Factors
Weak Year-to-Date Performance
The ETF has struggled overall this year, with negative year-to-date returns reflecting challenges in the sector.
Underperforming Top Holdings
Several of the largest positions, such as Tandem Diabetes Care and NovoCure, have seen significant declines this year, dragging down the fund.
Geographic Over-Concentration
The ETF is almost entirely invested in U.S. companies, limiting exposure to international markets and diversification.

XHE vs. SPDR S&P 500 ETF (SPY)

XHE Summary

The SPDR S&P Health Care Equipment ETF (XHE) is an investment fund that focuses on companies in the health care equipment and supplies industry. It follows the S&P Health Care Equipment Select Industry Index, which includes businesses leading medical innovation. Some well-known companies in this ETF are Medtronic and Hologic, both of which manufacture advanced medical devices. Investors might consider XHE for its potential growth, as health care equipment is essential and constantly evolving. However, new investors should note that this ETF is heavily concentrated in the health care sector, meaning its performance could be impacted by changes in health care regulations or industry trends.
How much will it cost me?The SPDR S&P Health Care Equipment ETF (XHE) has an expense ratio of 0.35%, meaning you’ll pay $3.50 per year for every $1,000 invested. This is slightly higher than average for ETFs because it is a sector-focused fund, which often requires more active management compared to broad-market index funds. However, it provides targeted exposure to the innovative health care equipment industry.
What would affect this ETF?The SPDR S&P Health Care Equipment ETF (XHE) could benefit from increased demand for innovative medical technologies and devices, driven by aging populations and advancements in health care. However, it may face challenges from regulatory changes, rising interest rates that impact growth-focused companies, or economic slowdowns that reduce health care spending. Its U.S.-focused portfolio and reliance on the health care equipment sector make it sensitive to domestic policy shifts and sector-specific trends.

XHE Top 10 Holdings

The SPDR S&P Health Care Equipment ETF (XHE) is leaning heavily into the innovative health care equipment sector, with a clear focus on U.S.-based companies. Rising stars like Alphatec Holdings and TransMedics Group are driving the fund’s performance, thanks to strong revenue growth and upbeat earnings calls. Meanwhile, Glaukos and Tandem Diabetes Care are holding the ETF back, struggling with profitability and bearish momentum. With nearly all its weight in health care, this fund is a bet on cutting-edge medical advancements, though some names are facing growing pains amid the sector’s rapid evolution.
Name
Company Name
Weight %
Market Value
Market Cap
Yearly Gain
Overall Rating
Inspire Medical Systems2.89%$4.59M$4.07B-27.70%
72
Outperform
AxoGen2.83%$4.50M$1.38B108.05%
69
Neutral
Tandem Diabetes Care2.82%$4.48M$1.45B-38.88%
61
Neutral
Haemonetics2.64%$4.20M$4.08B2.61%
70
Outperform
Globus Medical2.44%$3.88M$11.82B7.46%
82
Outperform
Omnicell2.25%$3.57M$1.97B-5.81%
71
Outperform
Alphatec Holdings2.21%$3.52M$3.10B105.26%
57
Neutral
Neogen2.03%$3.23M$1.52B-43.63%
50
Neutral
Glaukos2.02%$3.21M$6.24B-22.16%
61
Neutral
Align Tech2.01%$3.20M$11.81B-30.48%
74
Outperform

XHE Technical Analysis

Technical Analysis Sentiment
Positive
Last Price
Price Trends
50DMA
82.83
Positive
100DMA
81.39
Positive
200DMA
81.08
Positive
Market Momentum
MACD
2.02
Negative
RSI
66.90
Neutral
STOCH
66.01
Neutral
Evaluating momentum and price trends is crucial in ETF analysis to make informed investment decisions. For XHE, the sentiment is Positive. The current price of undefined is equal to the 20-day moving average (MA) of 86.44, equal to the 50-day MA of 82.83, and equal to the 200-day MA of 81.08, indicating a bullish trend. The MACD of 2.02 indicates Negative momentum. The RSI at 66.90 is Neutral, neither overbought nor oversold. The STOCH value of 66.01 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for XHE.

XHE Peer Comparison

Comparison Results
Name
Price
Price Target
AUM
Expense Ratio
Overall Rating
$156.30M0.35%
$935.55M0.62%
$794.94M0.38%
$754.87M0.38%
$746.47M0.40%
$348.80M0.51%
Performance Comparison
Ticker
Company Name
Price
Change
% Change
XHE
SPDR S&P Health Care Equipment ETF
89.80
-1.59
-1.74%
FXH
First Trust Health Care AlphaDEX Fund
IHE
iShares U.S. Pharmaceuticals ETF
IHF
iShares U.S. Healthcare Providers ETF
RSPH
Invesco S&P 500 Equal Weight Health Care ETF
PINK
Simplify Health Care ETF
Glossary
BuyAn ETF rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF is likely to deliver higher returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldAn ETF rated as a "Hold" s expected to perform in line with the overall market or a specific benchmark. This rating indicates that the ETF is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellAn ETF rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the ETF may deliver lower returns compared to other ETFs in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst ETF Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in ETFs carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: ―
Table of Contents
Advertisement